phosal 50 pg Search Results


phosal 50 pg  (TargetMol)
N/A
Phosal 50 PG is a standardized phosphatidylcholine concentrate
   Buy from Supplier
hy-y1903  (medchemexpress)
94
medchemexpress hy-y1903
Hy Y1903, supplied by medchemexpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/Phosal+50+PG/pmc12490250-58-0-4
Average 94 stars, based on 1 article reviews
hy-y1903 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
phosphatidylcholine phosal 50 pg  (lipoid gmbh)
90
lipoid gmbh phosphatidylcholine phosal 50 pg
Phosphatidylcholine Phosal 50 Pg, supplied by lipoid gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/phosphatidylcholine+phosal+50+pg/pmc11496697-108-14-21
Average 90 stars, based on 1 article reviews
phosphatidylcholine phosal 50 pg - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phosal 50 pg  (lipoid gmbh)
90
lipoid gmbh phosal 50 pg
Phosal 50 Pg, supplied by lipoid gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/phosal+50+pg/pmc11496697-108-16-21
Average 90 stars, based on 1 article reviews
phosal 50 pg - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phosal r 50 pg  (Merck KGaA)
90
Merck KGaA phosal r 50 pg
Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with <t>venetoclax</t> or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Phosal R 50 Pg, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/phosal+r+50+pg/pmc08498041-32-0-11
Average 90 stars, based on 1 article reviews
phosal r 50 pg - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phosal 50 pg lipoid 368315–31700201006  (lipoid gmbh)
90
lipoid gmbh phosal 50 pg lipoid 368315–31700201006
Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with <t>venetoclax</t> or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Phosal 50 Pg Lipoid 368315–31700201006, supplied by lipoid gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/phosal+50+pg+lipoid+368315+31700201006/10__1158_slash_1078___0432__ccr___22___0978-59-31-37
Average 90 stars, based on 1 article reviews
phosal 50 pg lipoid 368315–31700201006 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phosphatidylcholine in propylene glycol phosal 50 pg  (lipoid gmbh)
90
lipoid gmbh phosphatidylcholine in propylene glycol phosal 50 pg
Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with <t>venetoclax</t> or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Phosphatidylcholine In Propylene Glycol Phosal 50 Pg, supplied by lipoid gmbh, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/phosphatidylcholine+in+propylene+glycol+phosal+50+pg/pmc10635389-197-16-23
Average 90 stars, based on 1 article reviews
phosphatidylcholine in propylene glycol phosal 50 pg - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
60% phosal 50 pg (standardized phosphatidylcholine, pc, concentrate with at least 50% pc and propylene glycol)  (AbbVie Inc)
90
AbbVie Inc 60% phosal 50 pg (standardized phosphatidylcholine, pc, concentrate with at least 50% pc and propylene glycol)
Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with <t>venetoclax</t> or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
60% Phosal 50 Pg (Standardized Phosphatidylcholine, Pc, Concentrate With At Least 50% Pc And Propylene Glycol), supplied by AbbVie Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/60++phosal+50+pg++standardized+phosphatidylcholine++pc++concentrate+with+at+least+50++pc+and+propylene+glycol+/pmc06405759-317-13-31
Average 90 stars, based on 1 article reviews
60% phosal 50 pg (standardized phosphatidylcholine, pc, concentrate with at least 50% pc and propylene glycol) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phosal 50 pg  (Fisher Scientific)
86
Fisher Scientific phosal 50 pg
Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with <t>venetoclax</t> or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Phosal 50 Pg, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/50+pg+phosal/pmc07988687-39-0-4
Average 86 stars, based on 1 article reviews
phosal 50 pg - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
phosal® 50 pg  (BASF)
90
BASF phosal® 50 pg
Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with <t>venetoclax</t> or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Phosal® 50 Pg, supplied by BASF, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/phosal+50+pg/phosal++50+pg/pm20411409-98-13-41
Average 90 stars, based on 1 article reviews
phosal® 50 pg - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
phosal 50 pg  (Aladdin Scientific Corporation)
N/A
Phosal 50 PG is a cosolvent (standardised phosphatidylcholine concentrate). Phosal 50 PG as a carrier for lipophilic compounds, can improve the absorption, efficacy and therapeutic index of the active ingredient.Form:Liquid
   Buy from Supplier

Image Search Results


Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Journal: Frontiers in Immunology

Article Title: Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

doi: 10.3389/fimmu.2021.749094

Figure Lengend Snippet: Donor cell engraftment is dependent on recipient pre-alloSCT irradiation dose and treatment with BCL2 or JAK1/2 inhibitors. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. The following day mice were treated with RIC and alloSCT. (A) Donor cell engraftment (H2kd+ cells) was measured in the blood at day 21 post-alloSCT. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 2, 3, and 7, and BM was harvested and analysed by flow cytometry for the absolute number of (B–F) NK cells (NK1.1+CD3-), cNK (NKp46+CD49b+), M1 mature (CD11b+CD27+), M2 mature (CD11b+CD27-) and immature (CD11b-CD27+) NK cells; (G–L) naive (N; CD44-CD62L+); central memory (CM; CD44+CD62L+); effector memory (EM; CD44+CD62L-) CD4+ and CD8+ T cells. Data is representative of 3 independent experiments. Statistical analysis was performed using unpaired T test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: Venetoclax (100 mg/kg) and its vehicle (60% phosal R 50 PG (Merck, Germany), 30% polyethylene glycol (PEG) 400 (Merck, Germany), 10% ethanol) were administered by oral gavage once daily for two days, with a cumulative total dose of 4 mg. Ruxolitinib (180 mg/kg) and its vehicle (2% DMSO, 30% PEG 300 (Merck, Germany), ddH2O) were administered twice a day by oral gavage for two days, with a cumulative total dose of 14.4 mg.

Techniques: Irradiation, Flow Cytometry

Venetoclax and Ruxolitinib differentially affect MHC class-II and IFN-inducible gene expression. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 3, and 7, and gene expression was determined from BM RNA using the NanoString Mouse PanCancer Immune Profiling Panel. (A) Heat map of relative gene expression of H2-DMb2, H2-Ab1, H2-Eb1, H2-Aa, H2-Ob, CD74, Tap1, Rsad2, Klrb1 and Isg15 from venetoclax and ruxolitinib-treated mice. Relative expression of Rsad2, Klrb1, H2-DMB2 and CD74 (B–E) was compared between venetoclax or ruxolitinib-treated mice and their respective vehicle on day 1 post-treatment. The geometric mean of MHC-II expression on CD19+ B cells (F) , percentage of CD19+ B cells expressing MHC-II (G) , and the fold-change of MHC-II expression on total CD45+ BM cells from venetoclax or ruxolitinib-treated mice was compared to each vehicle control group (H) . Statistical analysis was performed using Mann-Whitney unpaired T test (B–E) , and unpaired T test (F–H) . *p < 0.05, **p < 0.01.

Journal: Frontiers in Immunology

Article Title: Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients

doi: 10.3389/fimmu.2021.749094

Figure Lengend Snippet: Venetoclax and Ruxolitinib differentially affect MHC class-II and IFN-inducible gene expression. WT mice were treated with venetoclax or ruxolitinib, or their respective vehicle for two days. Mice (n=3-4/group) were killed on days 1, 3, and 7, and gene expression was determined from BM RNA using the NanoString Mouse PanCancer Immune Profiling Panel. (A) Heat map of relative gene expression of H2-DMb2, H2-Ab1, H2-Eb1, H2-Aa, H2-Ob, CD74, Tap1, Rsad2, Klrb1 and Isg15 from venetoclax and ruxolitinib-treated mice. Relative expression of Rsad2, Klrb1, H2-DMB2 and CD74 (B–E) was compared between venetoclax or ruxolitinib-treated mice and their respective vehicle on day 1 post-treatment. The geometric mean of MHC-II expression on CD19+ B cells (F) , percentage of CD19+ B cells expressing MHC-II (G) , and the fold-change of MHC-II expression on total CD45+ BM cells from venetoclax or ruxolitinib-treated mice was compared to each vehicle control group (H) . Statistical analysis was performed using Mann-Whitney unpaired T test (B–E) , and unpaired T test (F–H) . *p < 0.05, **p < 0.01.

Article Snippet: Venetoclax (100 mg/kg) and its vehicle (60% phosal R 50 PG (Merck, Germany), 30% polyethylene glycol (PEG) 400 (Merck, Germany), 10% ethanol) were administered by oral gavage once daily for two days, with a cumulative total dose of 4 mg. Ruxolitinib (180 mg/kg) and its vehicle (2% DMSO, 30% PEG 300 (Merck, Germany), ddH2O) were administered twice a day by oral gavage for two days, with a cumulative total dose of 14.4 mg.

Techniques: Gene Expression, Expressing, Control, MANN-WHITNEY